Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout
Summary
Crystalys Therapeutics launched with $205 million in Series A funding to advance its gout therapy program. Novo Holdings, SR One, and Catalys Pacific co-led the round, with participation from a broad group of life sciences investors. The company will use the capital to push dotinurad through global Phase 3 trials and support its path toward regulatory approval and commercial launch. Crystalys says dotinurad has already shown strong efficacy and safety data in Asia, where it is approved and widely used.
Funding
Amount
$205.0M
Total raised
Date
September 30, 2025
Announcement date
Investors
Catalys Pacific Fund, Novo AS, Alexandria Venture Investments, S.R. One Ltd, Aberdeen Private Equity / Aberdeen Asset Management, Lightstone Ventures, Longwood Founders Fund, Pontifax, Wedbush
Lead investors
Company
crystalystx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected